Eli Lilly says its next big obesity shot is hitting numbers the weight-loss world used to associate with the operating room.
On Thursday, the company reported that patients on its experimental triple-agonist drug retatrutide lost roughly 28% of their body weight on average at the highest dose in late-stage trials. Traders and doctors quickly framed the results as surgery-level territory, even as they pointed to some tough side effects. Lilly said the data could pave the way for a commercial launch as soon as next year, turning up the heat in an already frantic market and setting up new fights over safety, access and what insurers will be willing to pay.
What Lilly’s trials showed
In a company release detailing its Phase 3 TRIUMPH program, Lilly said the 12 mg dose delivered the biggest impact, with patients losing about 28.7% of their body weight at 68 weeks. The company also reported that retatrutide improved pain and function in a subgroup of patients with knee osteoarthritis.
The most common side effects were gastrointestinal problems such as nausea, diarrhea and vomiting. Lilly added that sensory complaints, including dysesthesia, showed up more often at the highest dose, and that patients with higher baseline BMI accounted for most of the study withdrawals tied to adverse events. These topline results come from the company’s press materials and program summary. According to Eli Lilly, more detailed data will be rolled out at upcoming scientific meetings and then submitted for peer review.
How the market and press are reading the new numbers
Early coverage of the wider Phase 3 program has focused on just how far the numbers go. One round of reporting put the 12 mg dose at about 28.3% average weight loss over roughly 80 weeks, with the 4 mg arm coming in at about 19% over the same period. That reporting also noted that many Wall Street analysts were already baking in expectations of about 28% to 30% loss and warned that side-effect rates look higher than with some earlier obesity treatments. For that reporting and analyst commentary, see Reuters.
Where retatrutide sits next to approved drugs
Even using the more conservative published readouts, retatrutide’s Phase 3 performance edges past the average weight loss seen with today’s leading injectable medications.
For comparison, the SURMOUNT-1 trial of tirzepatide, now sold for weight loss as Zepbound, showed mean reductions of about 22.5% at the highest dose over 72 weeks. Those landmark tirzepatide data are laid out in the pivotal trial published in The New England Journal of Medicine, while Axios framed the new retatrutide results against benchmarks that have traditionally belonged to bariatric surgery.
What’s next: approvals, production and access
Lilly is running a multi-trial Phase 3 program for retatrutide, with more readouts scheduled through 2026. Reporting has indicated that the company aims to move toward regulatory filings and a possible commercial launch next year, assuming the remaining data look solid and regulators sign off. The company has also been pouring money into manufacturing capacity to keep up with expected demand and has highlighted both its pipeline and production buildout in recent investor materials.
For reporting on timelines and Lilly’s corporate commentary, see Lilly’s investor update alongside coverage from Reuters.
What patients and prescribers should know
For now, retatrutide is still an investigational drug and cannot be prescribed outside clinical trials. Lilly’s trial materials underscore that gastrointestinal side effects and sensory complaints became more common at higher doses and that some patients stopped treatment because of adverse events. Clinicians say that benefit-versus-tolerability balance is likely to be a central issue for health plans, regulators and prescribers if the drug reaches the market.
For the company’s breakdown of safety findings and trial context, see Eli Lilly, along with regulatory and trial commentary from Reuters.
